User login
A fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% (clindamycin-BP 3.75%) aqueous gel was effective and well tolerated in the treatment of moderate and severe acne vulgaris, reported Dr. Linda Stein Gold of Henry Ford Hospital in Detroit (J Drugs Dermatol. 2015;14[9]:969-74).
A multicenter, double-blind, randomized trial of 498 patients with moderate to severe acne showed that inflammatory and noninflammatory lesions were significantly reduced in patients who received treatment with clindamycin-BP 3.75% topical gel, compared with those in the vehicle group.
In patients with severe acne, 55.1% had a reduction of two grades or more in severity score at 12 weeks. In addition, 30.6% of patients assessed their acne as “clear” or “almost clear,” Dr. Stein Gold wrote. No participants withdrew from the study because of adverse events.
Read the article here.
A fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% (clindamycin-BP 3.75%) aqueous gel was effective and well tolerated in the treatment of moderate and severe acne vulgaris, reported Dr. Linda Stein Gold of Henry Ford Hospital in Detroit (J Drugs Dermatol. 2015;14[9]:969-74).
A multicenter, double-blind, randomized trial of 498 patients with moderate to severe acne showed that inflammatory and noninflammatory lesions were significantly reduced in patients who received treatment with clindamycin-BP 3.75% topical gel, compared with those in the vehicle group.
In patients with severe acne, 55.1% had a reduction of two grades or more in severity score at 12 weeks. In addition, 30.6% of patients assessed their acne as “clear” or “almost clear,” Dr. Stein Gold wrote. No participants withdrew from the study because of adverse events.
Read the article here.
A fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% (clindamycin-BP 3.75%) aqueous gel was effective and well tolerated in the treatment of moderate and severe acne vulgaris, reported Dr. Linda Stein Gold of Henry Ford Hospital in Detroit (J Drugs Dermatol. 2015;14[9]:969-74).
A multicenter, double-blind, randomized trial of 498 patients with moderate to severe acne showed that inflammatory and noninflammatory lesions were significantly reduced in patients who received treatment with clindamycin-BP 3.75% topical gel, compared with those in the vehicle group.
In patients with severe acne, 55.1% had a reduction of two grades or more in severity score at 12 weeks. In addition, 30.6% of patients assessed their acne as “clear” or “almost clear,” Dr. Stein Gold wrote. No participants withdrew from the study because of adverse events.
Read the article here.
